Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Paolo Pola is active.

Publication


Featured researches published by Paolo Pola.


The Lancet | 1998

Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori

Antonio Gasbarrini; Francesco Franceschi; Raffaele Tartaglione; Raffaele Landolfi; Paolo Pola; Giovanni Gasbarrini

1 Negrini R, Savio A, Poiesi C, et al. Antigenic minicry between H pylori and gastric mucosa in the pathogenesis of body atrophic gastritis. Gastreonterology 1996; 111: 655–65. 2 Ko GH, Part HB, Shin MK, et al. Monoclonal antibodies against Helicobacter pylori cross-react with human tissue. Helicobacter 1997; 4: 210–15. 3 Nagachima R, Maeda K, Yuda F, Kudo K, Saitoh M, Takahashi T. Helicobacter pylori antigen in the glomeruli of patients with membranous nephropathy. Virchows Arch 1997; 431: 235–39. 4 Machet L, Vaillant L, Machet MC, Buchler M, Lorette G. SchonleinHenoch purpura associated with gastric Helicobacter pylori infection. Dermatology 1997; 194: 86. 5 Francois B, Trimoreau F, Vignon P, Fixe P, Praloran V, Gastinne H. Thrombocytopenia in the sepsis syndrome: role of hemophagocytosis and macrophage colony-stimulating factor. Am J Med 1997; 103: 114–20.


Alimentary Pharmacology & Therapeutics | 2001

The effect of oral administration of Lactobacillus GG on antibiotic‐associated gastrointestinal side‐effects during Helicobacter pylori eradication therapy

Alessandro Armuzzi; Filippo Cremonini; F. Bartolozzi; Filippo Canducci; Marcello Candelli; Veronica Ojetti; Giovanni Cammarota; M Anti; A. De Lorenzo; Paolo Pola; Giovanni Gasbarrini; Antonio Gasbarrini

One‐week triple therapy is currently considered the golden standard against Helicobacter pylori. However, gastrointestinal side‐effects are among the major pitfalls in such regimens. Probiotic supplementation might help to prevent or reduce such drug‐related manifestations.


Alimentary Pharmacology & Therapeutics | 2000

A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates

Filippo Canducci; Alessandro Armuzzi; Filippo Cremonini; Giovanni Cammarota; F. Bartolozzi; Paolo Pola; Giovanni Gasbarrini; Antonio Gasbarrini

Acid suppression plus two antibiotics is considered the reference anti‐Helicobacter pylori treatment. Reported eradication rates are around 65–80%. Human Lactobacillus acidophilus shows an in vitro inhibitory effect on the attachment of H. pylori to gastric epithelial cell lines. Culture supernatant of this bacillus seems to decrease the in vitro viability of H. pylori.


Alimentary Pharmacology & Therapeutics | 2005

Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth.

Gabriella Nucera; Maurizio Gabrielli; Andrea Lupascu; Ernesto Cristiano Lauritano; Angelo Santoliquido; Filippo Cremonini; Giovanni Cammarota; Paolo Tondi; Paolo Pola; Giovanni Gasbarrini; Antonio Gasbarrini

Background : Small intestinal bacterial overgrowth and sugar malabsorption (lactose, fructose, sorbitol) may play a role in irritable bowel syndrome. The lactulose breath test is a reliable and non‐invasive test for the diagnosis of small intestinal bacterial overgrowth. The lactose, fructose and sorbitol hydrogen breath tests are widely used to detect specific sugar malabsorption.


Alimentary Pharmacology & Therapeutics | 2005

Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case–control study in irritable bowel syndrome

Andrea Lupascu; Maurizio Gabrielli; Ernesto Cristiano Lauritano; Emidio Scarpellini; Angelo Santoliquido; Giovanni Cammarota; Roberto Antonio Flore; Paolo Tondi; Paolo Pola; Giovanni Gasbarrini; Antonio Gasbarrini

Background:  Studies assessing the prevalence of small intestinal bacterial overgrowth in irritable bowel syndrome gave contrasting results. Differences in criteria to define irritable bowel syndrome patients and methods to assess small intestinal bacterial overgrowth may explain different results. Moreover, no data exist on small intestinal bacterial overgrowth prevalence in a significant population of healthy non‐irritable bowel syndrome subjects.


Stroke | 2004

Proinflammatory Genetic Profiles in Subjects With History of Ischemic Stroke

Andrea Flex; Eleonora Gaetani; Pierangelo Papaleo; Giuseppe Straface; Anna S. Proia; Giovanni Pecorini; Paolo Tondi; Paolo Pola; Roberto Pola

Background and Purpose— Proinflammatory genetic profiles, resulting from the combination of single nucleotide polymorphisms in genes encoding inflammatory molecules, may contribute to the development and progression of cardiovascular diseases. We evaluated the association between history of ischemic stroke and genetic profiles determined by the synergistic effects of polymorphisms in genes encoding prototypical inflammatory proteins. Methods— The study included 237 individuals with history of ischemic stroke and 223 age-matched and gender-matched controls. The polymorphisms of the C-reactive protein (CRP), interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), monocyte chemoattractant protein-1 (MCP-1), intercellular adhesion molecule-1 (ICAM-1), E-selectin (E-sel), and matrix metalloproteinase-3 (MMP-3) genes were studied. Results— IL-6 GG, IL-6 GC, MCP-1 GG, ICAM-1 EE, E-sel AA, and MMP-3 5A5A genotypes were significantly and independently associated with stroke history. The odds of stroke increased with the number of high-risk genotypes: carrying 1 proinflammatory gene variant conferred a risk of 3.3 (1.6 to 6.9), whereas individuals concomitantly carrying 2 and 3 proinflammatory gene variants had adjusted odds ratios of 21.0 (7.6 to 57.5) and 50.3 (10.2 to 248.1), respectively. Conclusions— Proinflammatory genetic profiles are significantly more common in subjects with stroke history. Synergistic effects between proinflammatory genotypes might be potential markers for cerebrovascular diseases.


Digestion | 2001

Effect of Lactobacillus GG Supplementation on Antibiotic-Associated Gastrointestinal Side Effects during Helicobacter pylori Eradication Therapy: A Pilot Study

Alessandro Armuzzi; Filippo Cremonini; Veronica Ojetti; Francesco Bartolozzi; Filippo Canducci; Marcello Candelli; Luca Santarelli; Giovanni Cammarota; A. De Lorenzo; Paolo Pola; Giovanni Gasbarrini; Antonio Gasbarrini

Background: One-week triple therapy is currently regarded as the reference of anti-Helicobacter pylori treatment. However, antibiotic-associated gastrointestinal side effects are among the major pitfalls of such regimens. Probiotic supplementation may be regarded as a therapeutic tool to prevent or reduce these troublesome drug-related manifestations. Aim: To determine whether the addition of the probiotic Lactobacillus GG to an anti-H. pylori standard triple therapy could help to prevent or minimize the occurrence of gastrointestinal side effects. Methods: One hundred and twenty healthy asymptomatic subjects screened positive for H. pylori infection and deciding to receive eradication therapy were randomized either to 1-week pantoprazole (40 mg b.i.d.), clarithromycin (500 mg b.i.d.), tinidazole (500 mg b.i.d.) or to the same regimen supplemented with Lactobacillus GG for 14 days. Patients filled in validated questionnaires during follow-up to determine the type and severity of side effects and to judge overall tolerability. Results: Bloating, diarrhea and taste disturbances were the most frequent side effects during the eradication week and were significantly reduced in the Lactobacillus GG-supplemented group (RR = 0.4, CI 0.2–0.8; RR = 0.3, CI 0.1–0.8; RR = 0.3, CI 0.1–0.7, respectively). The same pattern was observed throughout the follow-up period. Overall assessment of treatment tolerability showed a significant trend in favor of the Lactobacillus GG-supplemented group (p = 0.03). Conclusions:Lactobacillus GG supplementation beneficially affects H. pylori therapy-related side effects and overall treatment tolerance.


Digestive Diseases and Sciences | 1998

Beneficial Effects of Helicobacter pylori Eradication on Idiopathic Chronic Urticaria

Cristiana Di Campli; Antonio Gasbarrini; Eleonora Nucera; Francesco Franceschi; Veronica Ojetti; Elena Sanz Torre; Domenico Schiavino; Paolo Pola; Giampiero Patriarca; Giovanni Gasbarrini

Helicobacter pylori, the most important cause ofgastritis and peptic ulcer, recently has been associatedwith several extradigestive diseases. The aim of thisstudy was to assess the prevalence of Helicobacter pylori infection and the effects of bacteriumeradication in 42 consecutive patients affected byidiopathic chronic urticaria. Helicobacter pylori wasassessed by [13C]urea breath test.Amoxicillin, clarithromycin, and lansoprazole were given to infectedpatients for seven days. Urticaria and gastrointestinalsymptoms were assessed on enrollment and aftereradication. Fifty-five percent of patients proved to beinfected by Helicobacter pylori. Prevalence ofgastrointestinal symptoms did not differ betweeninfected and uninfected patients. Eighty-eight percentof infected patients in whom the bacterium waseradicated after therapy showed a total or partial remission ofurticaria symptoms. Conversely, symptoms remainedunchanged in all uninfected patients. In conclusion,Helicobacter pylori affects a high percentage ofpatients with idiopathic chronic urticaria; however,typical gastrointestinal symptoms do not identifyinfection status. Bacterium eradication is associatedwith a remission of urticaria symptoms, suggesting apossible role of Helicobacter pylori in the pathogenesisof this skin disorder.


Circulation | 2002

Cross-Reactivity of Anti-CagA Antibodies With Vascular Wall Antigens Possible Pathogenic Link Between Helicobacter pylori Infection and Atherosclerosis

Francesco Franceschi; Antonia R. Sepulveda; Antonio Gasbarrini; Paolo Pola; Nicolò Gentiloni Silveri; Giovanni Gasbarrini; David Y. Graham; Robert M. Genta

Background—Helicobacter pylori-CagA positive strains have been shown to be associated with atherosclerosis. However, the pathogenesis is still undetermined. The aim of this study was to determine whether anti-CagA antibodies cross-react with antigens of normal and atherosclerotic arteries. Methods and Results—Eight umbilical cord sections, 14 atherosclerotic artery sections, and 10 gastrointestinal tract sections were examined by immunohistochemistry using polyclonal anti-CagA antibodies. Five atherosclerotic and 3 normal artery samples were also lysed in ice-cold lysis buffer containing protease inhibitors and were immunoprecipitated using the same antibodies. Anti-CagA antibodies reacted with cytoplasm and nuclei of smooth muscle cells in umbilical cord and atherosclerotic vessel sections, cytoplasm of fibroblasts-like cells in intimal atherosclerotic plaques, and the cell membranes of endothelial cells. Anti-CagA antibodies also specifically immunoprecipitated 2 high molecular weight antigens of 160 and 180 kDa from both normal and atherosclerotic artery lysates. Conclusions—Anti-CagA antibodies cross-react with antigens of both normal and atherosclerotic blood vessels. We speculate that the binding of anti-CagA antibodies to those antigens in injured arteries could influence the progression of atherosclerosis in CagA-positive H pylori-infected patients.


The Journal of Thoracic and Cardiovascular Surgery | 1996

Safe removal of the radial artery for myocardial revascularization: A doppler study to prevent ischemic complications to the hand

Paolo Pola; Michele Serricchio; Roberto Antonio Flore; Eric Manasse; Angela Favuzzi; Gian Federico Possati

Radial artery harvesting has recently been reintroduced for myocardial revascularization. Harvesting the radial artery may jeopardize the vascularization of the hand; cautious selection of candidates must therefore be pursued. The study involved 188 consecutive patients. We verified the patency of the upper limbs arteries and the adequacy of the ulnar supply by static and dynamic Doppler evaluations. The use of the radial artery was contraindicated in 14 cases (three for stenosis of the subclavian artery and 11 for inadequate collateralization). One hundred patients were operated on with the radial artery used as a graft; the remaining 74 patients had a different conduit placed. The vascularization of the hand was restudied within 10 days in all patients who underwent operation; in 63 patients, it was studied again at 1 year. The early Doppler examination showed significant increase in blood flow velocities in the ulnar artery, with a flow redistribution in the common digital palmar arteries (decreased in the first and increased in the second and the third). The late Doppler examination showed superimposable findings. No local ischemic complications were observed. We conclude that Doppler study is a useful tool in preoperative screening of candidates for radial artery harvesting for myocardial revascularization.

Collaboration


Dive into the Paolo Pola's collaboration.

Top Co-Authors

Avatar

Antonio Gasbarrini

Catholic University of the Sacred Heart

View shared research outputs
Top Co-Authors

Avatar

Giovanni Gasbarrini

The Catholic University of America

View shared research outputs
Top Co-Authors

Avatar

Paolo Tondi

The Catholic University of America

View shared research outputs
Top Co-Authors

Avatar

Michele Serricchio

Catholic University of the Sacred Heart

View shared research outputs
Top Co-Authors

Avatar

Marcello Candelli

The Catholic University of America

View shared research outputs
Top Co-Authors

Avatar

Maurizio Gabrielli

The Catholic University of America

View shared research outputs
Top Co-Authors

Avatar

Roberto Pola

The Catholic University of America

View shared research outputs
Top Co-Authors

Avatar

Angelo Santoliquido

Catholic University of the Sacred Heart

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Roberto Antonio Flore

Catholic University of the Sacred Heart

View shared research outputs
Researchain Logo
Decentralizing Knowledge